Evidence map›Paper›PMID 36157448›Full record

ArticleFrontiers in endocrinology2022

Lipocalin-2 is associated with FGF23 in WNT1 and PLS3 osteoporosis.

Petra Loid, Helena Hauta-Alus, Outi Mäkitie, Per Magnusson, Riikka E Mäkitie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Petra LoidFolkhälsan Research Center, Genetics Research Program, Helsinki, Finland.
Helena Hauta-AlusChildren's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Outi MäkitieFolkhälsan Research Center, Genetics Research Program, Helsinki, Finland.
Per MagnussonDepartment of Clinical Chemistry, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Riikka E MäkitieFolkhälsan Research Center, Genetics Research Program, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The pathogenic mechanisms of early-onset osteoporosis caused by Objective: We aimed to investigate if plasma lipocalin-2 could be utilized as a biomarker for WNT1 and PLS3 osteoporosis and to evaluate the association between lipocalin-2 and other parameters of bone metabolism. Methods: We measured plasma lipocalin-2 in 17 Results: We found no differences in plasma lipocalin-2 levels in WNT1 or PLS3 patients compared with MN subjects. However, lipocalin-2 was associated with C-terminal FGF23 in WNT1 patients ( Conclusion: We conclude that plasma lipocalin-2 is not altered in

Indexed as

Collagen Type IOsteoporosisAlkaline PhosphataseBiomarkersFerritinsFibroblast Growth FactorsHumansIronLipocalin-2Receptors, TransferrinTransferrinsAlkaline PhosphataseBiomarkersCollagen Type IFerritinsFibroblast Growth FactorsIronLipocalin-2Receptors, TransferrinTransferrinsbone biomarkersFGF23lipocalin-2monogenic osteoporosisPLS3WNT1

Identifiers

PMID36157448
PMCPMC9493469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.